Oppenheimer Asset Management’s Kyntra Bio KYNB Stock Holding History

Oppenheimer Asset Management’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-377	Closed	-$327K	–	1211
2021 Q1	$327K	Sell	377 -10	-3%	-$10.6K	0.01%	1011
2020 Q4	$359K	Sell	387 -286	-42%	-$301K	0.01%	956
2020 Q3	$692K	Buy	673 +209	+45%	+$225K	0.01%	720
2020 Q2	$470K	Buy	464 +4	+0.9%	+$3.71K	0.01%	811
2020 Q1	$400K	Sell	460 -9	-2%	-$8.95K	0.01%	798
2019 Q4	$502K	Buy	469 +49	+12%	+$50K	0.01%	815
2019 Q3	$388K	Sell	420 -8	-2%	-$8.79K	0.01%	864
2019 Q2	$483K	Buy	428 +38	+10%	+$41.6K	0.01%	824
2019 Q1	$530K	Buy	+390	New	+$529K	0.01%	789
2018 Q3	–	Sell	-151	Closed	-$236K	–	1152
2018 Q2	$236K	Buy	+151	New	+$197K	0.01%	1026
2018 Q1	–	Sell	-176	Closed	-$237K	–	1143
2017 Q4	$237K	Hold	176	–	–	0.01%	999
2017 Q3	$237K	Buy	176 +93	+112%	+$98K	0.01%	1004
2017 Q2	$67K	Sell	83 -52	-39%	-$36.2K	﹤0.01%	1282
2017 Q1	$83K	Buy	+135	New	+$82.2K	﹤0.01%	1237

Other funds holding KYNB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Oppenheimer Asset Management's KYNB Position: Q2 2021 in Review

Oppenheimer Asset Management sold out of Kyntra Bio (KYNB) in Q2 2021, closing a stake of 377 shares — an estimated $327K sold.

Oppenheimer Asset Management first reported a position in KYNB in Q1 2017 and held it in 14 quarters. The position peaked at $692K in Q3 2020. 174 funds tracked by Wall St. Rank hold KYNB as of Q2 2021.

Oppenheimer Asset Management reported no remaining Kyntra Bio position as of Q2 2021 after selling out during the quarter.
Oppenheimer Asset Management sold 377 Kyntra Bio shares in Q2 2021, an estimated $327K.
Oppenheimer Asset Management first reported a position in Kyntra Bio in Q1 2017 and held it in 14 quarters.
Oppenheimer Asset Management's Kyntra Bio position peaked at $692K in Q3 2020.
174 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2021.

Based on Oppenheimer Asset Management's 13F filing for Q2 2021, filed 3 Aug 2021.